Highly Multiplexed Broad Pathogen Assay Detects Infectious Diseases
By LabMedica International staff writers Posted on 29 Nov 2018 |
Image: The nCounter platform provides a simple and cost effective solution for multiplex analysis of up to 800 RNA, DNA, or protein targets from diverse samples (Photo courtesy of NanoString).
Identifying the causative agent in an acute febrile illness can be challenging diagnostically, especially when organisms in a particular region have overlapping clinical presentation or when that pathogen’s presence is unexpected.
Rapid pathogen identification during an acute febrile illness is a critical first step for providing appropriate clinical care and patient isolation. Primary screening using sensitive and specific assays, such as real-time polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assays (ELISAs), can rapidly test for known circulating infectious diseases.
Scientists at the United States Army Medical Research Institute of Infectious Diseases (Fort Detrick, MD, USA) developed a highly multiplexed assay designed to detect 164 different viruses, bacteria, and parasites using the NanoString nCounter platform. Included in this assay were high consequence pathogens such as Ebola virus, highly endemic organisms including several Plasmodium species, and a large number of less prevalent pathogens to ensure a broad coverage of potential human pathogens.
The team used the Broad Pathogen Detection Assay (BPDA) for use with the NanoString nCounter platform in order to quickly screen a sample for multiple pathogens in a single tube reaction. Mock clinical samples were prepared in order to evaluate the ability of the BPDA to detect samples that had been extracted from whole human blood. Evaluation of the panel resulted in positive detection of 113 (encompassing 98 different human pathogen types) of the 126 organisms available to us including the medically important Ebola virus, Lassa virus, dengue virus serotypes 1–4, Chikungunya virus, yellow fever virus, and Plasmodium falciparum.
The authors concluded that the hands on time and sample volume requirement are minimal for the BPDA. The assay performed well in mock clinical and human clinical samples, demonstrating the clinical utility of this assay in cases where the initial diagnostic testing results in negative results. Overall, this assay could improve infectious disease diagnostics and biosurveillance efforts as a quick, highly multiplexed, and easy to use pathogen-screening tool. The study was published on November 5, 2018, in the journal Public Library of Science Neglected Tropical Diseases.
Related Links:
United States Army Medical Research Institute of Infectious Diseases
Rapid pathogen identification during an acute febrile illness is a critical first step for providing appropriate clinical care and patient isolation. Primary screening using sensitive and specific assays, such as real-time polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assays (ELISAs), can rapidly test for known circulating infectious diseases.
Scientists at the United States Army Medical Research Institute of Infectious Diseases (Fort Detrick, MD, USA) developed a highly multiplexed assay designed to detect 164 different viruses, bacteria, and parasites using the NanoString nCounter platform. Included in this assay were high consequence pathogens such as Ebola virus, highly endemic organisms including several Plasmodium species, and a large number of less prevalent pathogens to ensure a broad coverage of potential human pathogens.
The team used the Broad Pathogen Detection Assay (BPDA) for use with the NanoString nCounter platform in order to quickly screen a sample for multiple pathogens in a single tube reaction. Mock clinical samples were prepared in order to evaluate the ability of the BPDA to detect samples that had been extracted from whole human blood. Evaluation of the panel resulted in positive detection of 113 (encompassing 98 different human pathogen types) of the 126 organisms available to us including the medically important Ebola virus, Lassa virus, dengue virus serotypes 1–4, Chikungunya virus, yellow fever virus, and Plasmodium falciparum.
The authors concluded that the hands on time and sample volume requirement are minimal for the BPDA. The assay performed well in mock clinical and human clinical samples, demonstrating the clinical utility of this assay in cases where the initial diagnostic testing results in negative results. Overall, this assay could improve infectious disease diagnostics and biosurveillance efforts as a quick, highly multiplexed, and easy to use pathogen-screening tool. The study was published on November 5, 2018, in the journal Public Library of Science Neglected Tropical Diseases.
Related Links:
United States Army Medical Research Institute of Infectious Diseases
Latest Microbiology News
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia
- Rapid AST Platform Provides Targeted Therapeutic Results Days Faster Than Current Standard of Care
- New Analysis Method Detects Pathogens in Blood Faster and More Accurately by Melting DNA
- Rapid Sepsis Test Delivers Two Days Faster Results